USMLE Step 1 practice question: Phenytoin zero-order (Michaelis-Menten) elimination kinetics

USMLE Step 1PharmacologyPharmacology

A 29-year-old man comes to the physician because of a 1-week history of unsteady gait, slurred speech, and double vision. He has focal epilepsy that had been well controlled with phenytoin, 300 mg daily; 6 months ago, his steady-state trough serum phenytoin concentration was 11 µg/mL (therapeutic range 10–20). Four weeks ago, after a breakthrough seizure, his dose was increased to 400 mg daily. He takes the medication as prescribed and takes no other medications or supplements. He does not drink alcohol. Vital signs are within normal limits. Examination shows horizontal nystagmus on lateral gaze, dysarthria, and a wide-based, ataxic gait. Serum albumin concentration is 4.3 g/dL, and liver function tests and serum creatinine concentration are within normal limits. His total serum phenytoin concentration is now 31 µg/mL.

Which of the following best explains the disproportionate increase in this patient's serum drug concentration?

  1. Displacement of the drug from plasma albumin binding sites
  2. Reduced renal tubular secretion of the unchanged drug
  3. Inhibition of its metabolizing enzyme by a coadministered drug
  4. Saturation of its hepatic metabolizing enzymes within the therapeutic range
  5. Accumulation of a pharmacologically active hepatic metabolite
Show answer and explanation

Correct answer: D. Saturation of its hepatic metabolizing enzymes within the therapeutic range

This patient has phenytoin toxicity (nystagmus, ataxia, dysarthria, diplopia) after a modest dose increase. A 33% increase in dose (300 → 400 mg/day) produced a nearly 3-fold increase in serum concentration (11 → 31 µg/mL). With first-order (linear) kinetics, steady-state concentration is directly proportional to the dosing rate, so the expected new level would have been about 15 µg/mL.

Phenytoin is eliminated almost entirely by hepatic metabolism (mainly CYP2C9, with a smaller contribution from CYP2C19), and these enzymes have a Michaelis constant (Km) that lies within or below the therapeutic concentration range. According to Michaelis-Menten kinetics, the rate of elimination = Vmax × C / (Km + C). When C is well below Km, elimination is proportional to concentration (first-order kinetics: a constant fraction of drug is eliminated per unit time). As C rises above Km, the enzymes become saturated and elimination approaches Vmax, a constant amount per unit time (zero-order kinetics). Small increases in dose then cause disproportionately large increases in steady-state concentration, the apparent half-life lengthens, and the time to reach a new steady state is prolonged. For this reason, phenytoin doses are increased in small increments (eg, 25–50 mg/day) with close monitoring of serum levels. Other drugs with clinically important zero-order (saturable) elimination include ethanol and high-dose aspirin.

High-yield summary: Zero-order elimination = constant AMOUNT per unit time (phenytoin, ethanol, high-dose aspirin—‘PEA’); first-order elimination = constant FRACTION per unit time. Saturable kinetics → small dose increase, large rise in level. In hypoalbuminemia, the free fraction of phenytoin rises, so free levels should be measured.

Why the other options are wrong

  • A. Displacement of the drug from plasma albumin binding sites — Displacement from albumin (eg, by valproate or uremia) or hypoalbuminemia increases the free fraction, but the total concentration stays the same or decreases; this patient has normal albumin, no interacting drugs, and a markedly increased total concentration.
  • B. Reduced renal tubular secretion of the unchanged drug — Phenytoin is cleared almost exclusively by hepatic metabolism, with <5% excreted unchanged in the urine, and this patient's renal function is normal.
  • C. Inhibition of its metabolizing enzyme by a coadministered drug — Inhibitors of CYP2C9 (eg, fluconazole, amiodarone, trimethoprim-sulfamethoxazole) can raise phenytoin levels, but this patient takes no other medications or supplements.
  • E. Accumulation of a pharmacologically active hepatic metabolite — Phenytoin is metabolized mainly to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), which is pharmacologically inactive; toxicity reflects the concentration of the parent drug, which is what was measured.

Key point

Phenytoin undergoes saturable (Michaelis-Menten) hepatic metabolism, so near the therapeutic range elimination shifts to zero-order kinetics and small dose increases cause disproportionate rises in serum concentration.

Memory hook

Zero-order trio ‘PEA’ (Phenytoin, Ethanol, Aspirin)—a pea is round like a 0: a little more dose, a lot more level.

Share: Telegram WhatsApp X LinkedIn

Practice like this every day

15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.

Play free

More free questions in this system

Pharmacokinetics: volume of distribution and oral loading doseUSMLE Step 1 · PharmacologyChronic aortic regurgitationUSMLE Step 1 · CardiovascularAutosomal recessive recurrence risk (cystic fibrosis, unaffected sibling = 2/3 carrier)USMLE Step 1 · GeneticsAcyclovir-resistant HSV: thymidine kinase deficiencyUSMLE Step 1 · MicrobiologyCisplatin toxicity (ototoxicity, nephrotoxicity, hypomagnesemia): DNA cross-linkingUSMLE Step 1 · Hematology/OncologyKallmann syndrome: failed GnRH neuron migration from the olfactory placodeUSMLE Step 1 · Reproductive

All free questions →